Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma

IMPORTANCE: Anti–programmable cell death-1 (anti–PD-1) improves relapse-free survival when used as adjuvant therapy for high-risk resected melanoma. However, it can lead to immune-related adverse events (irAEs), which become chronic in approximately 40% of patients with high-risk melanoma treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Goodman, Rachel S., Lawless, Aleigha, Woodford, Rachel, Fa’ak, Faisal, Tipirneni, Asha, Patrinely, J. Randall, Yeoh, Hui Ling, Rapisuwon, Suthee, Haydon, Andrew, Osman, Iman, Mehnert, Janice M., Long, Georgina V., Sullivan, Ryan J., Carlino, Matteo S., Menzies, Alexander M., Johnson, Douglas B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401300/
https://www.ncbi.nlm.nih.gov/pubmed/37535354
http://dx.doi.org/10.1001/jamanetworkopen.2023.27145

Ejemplares similares

Ejemplares similares